HealthBiogen Advances Alzheimer's Drug Diranersen to Late-Stage Trials
Biogen announced it will advance its experimental Alzheimer's drug, Diranersen, to late-stage development following a mid-stage study that demonstrated the drug slowed cognitive decline and reduced a key brain marker. The decision comes despite mixed results from earlier trials, highlighting Biogen's commitment to further testing the drug's efficacy.
Business Medical Dialogues··Bengaluru


